Market revenue in 2023 | USD 916.0 million |
Market revenue in 2030 | USD 1,558.1 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 62.43% in 2023. Horizon Databook has segmented the Middle East & Africa asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The MEA market includes South Africa, Saudi Arabia, and the United Arab Emirates (UAE). The rapid economic development in emerging markets, such as South Africa, the high unmet healthcare needs, and increasing prevalence of respiratory disorders are some of the key drivers propelling growth in the region. In the Middle East, around 60 million individuals are at risk of developing a respiratory disease.
Due to its high incidence and social & economic consequences, COPD, asthma, respiratory allergies, and occupational lung disorders are major public health issues in emerging countries, especially the Middle East/North Africa (MENA) countries. In addition, the increasing government initiatives and growing partnerships between key players & healthcare providers are anticipated to propel market growth over the forecast period.
Moreover, Approximately 40 million people today have various respiratory disorders, and over 60% to 70% of individuals diagnosed with a respiratory illness are under the age of 40, with smokers accounting for 30% of those diagnosed. As a result, around 60 million individuals in MEA are at risk of contracting respiratory disorders.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa asthma therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account